Press Releases

The subscription period for the series TO 1 warrants issued as part of Initiator Pharma A/S’s (“Initiator Pharma”) rights issue conducted during the spring of 2018 will continue until November 1, 2018. The last day for trading with the series TO 1 warrants is October 30, 2018. Holders of the series TO 1 warrants are entitled to subscribe for one new share for each warrant at a price of SEK 2.20 per share. If all of the series TO 1 warrants are exercised, 5,789,294 new shares are emitted, and Initiator Pharma is allocated approximately SEK 12.7 million before issue costs.

Initiator Pharma, a Biotech Company developing a novel treatment of Erectile Dysfunction (ED), have received approval to conduct our first clinical trial with Drug Candidate IPED2015.

Initiator Pharma, a Biotech Company developing a novel treatment of Erectile Dysfunction (ED), will be collaborating with MAC Clinical Research Early Phase Unit, an MHRA Accredited Unit in Manchester UK to complete their first clinical trial for drug candidate IPED2015.

Initiator Pharma, a Biotech Company developing a novel treatment of Erectile Dysfunction (ED), has today filed a Clinical Trial Application, CTA for Drug candidate IPED2015 with the Medicines & Healthcare productsRegulatory Agency, MHRA,UK.

In March 2018, Initiator Pharma A/S (“Initiator Pharma”) conducted a rights issue in which the public also were given the opportunity to subscribe for units. Through the rights issue, a total of 8.683.941 shares and a total of 5.789.294 share options of series TO 1 were issued. Last day of trading in BTUs (paid subscription unit) is April 26th, 2018 and stop date is April 30th, 2018.

Initiator Pharma A/S (“Initiator Pharma”) today, on April 5th, 2018, announces that the rights issue of units has been oversubscribed. The rights issue was subscribed to approximately SEK 20,6 million, responding to a subscription rate of approximately 108 percent. Through the rights issue a total of 8.683.941 shares and a total of 5.789.294 share options of series TO 1 are issued and Initiator Pharma are provided approximately SEK 19.1 million before issuing costs. The issuing costs are calculated to amount to approximately SEK 2,3 million, of which approximately SEK 0,56 million are related to compensation for subscription guarantees. Since the rights issue was oversubscribed, the subscription guarantees are not activated. Contract notes are planned to be sent out today, on April 5th, 2018.

Today, on March 15th, 2018, the subscription period in Initiator Pharma A/S’s (“Initiator Pharma”) rights issue of units, starts. The rights issue is also open to the public. The subscription period ends on March 29th, 2018. A fully subscribed initial issue provides Initiator Pharma with approximately SEK 19.1 million before issuing costs. In addition, the company can be provided with a further approximately SEK 12,7 million in case the initial issue is fully subscribed and all of the attached free-of-charge warrants of series TO 1 are exercised. In total, the offer thereby comprises a maximum of approximately SEK 31.8 million before issuing costs. Initiator Pharma agreed in writing prior to the rights issue on subscription commitments for a total of around SEK 8 million and guarantee subscription totalling approximately SEK 5.5 million. Hence, around SEK 13.5 million, corresponding to 70 percent of the initial issue amount, has been agreed in advance in writing. Prospectus, teaser and subscription form without preferential rights are available on the websites of the company (www.initiatorpharma.com), AktieTorget (www.aktietorget.se) and Sedermera Fondkommission (www.sedermera.se). Subscription through Bank-ID is also available at Sedermera Fondkommission’s website.

Initiator Pharma A/S (“Initiator Pharma”) hereby publishes prospectus concerning the rights issue of units starting on March 15th, 2018. The prospectus is available via the company’s (www.initiatorpharma.com), AktieTorget’s (www.aktietorget.se) and Sedermera Fondkommission’s (www.sedermera.se) respective websites. Teaser and subscription form without subscription rights will be published in connection with the start of the subscription period.